Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Catalent Cuts Workforce in Ongoing Restructuring | Contract Pharma

What are you searching for?

Sign in
Breaking News

Catalent Cuts Workforce in Ongoing Restructuring

To cut approximately 300 employees in its Biologics and Pharma and Consumer Health segments.

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Catalent, a global CDMO headquartered in Somerset, NJ, plans to cut approximately 300 employees in its Biologics and Pharma and Consumer Health segments as part of its restructuring plans to reduce costs and consolidate facilities.

Employee and non-employee restructuring charges associated with Catalent’s plans to reduce costs, consolidate facilities, and optimize its infrastructure across the organization were $30 million in the company’s fiscal second quarter and $17 million three months ended December 31, 2023.
 
On February 5, Catalent announced it had entered into a merger agreement under which Novo Holdings, an investment company responsible for managing the assets and wealth of the Novo Nordisk Foundation, will acquire Catalent in an all-cash transaction that values Catalent at $16.5 billion. The transaction would boost Semaglutide supply, which Novo Nordisk markets as Ozempic for type 2 diabetes and Wegovy for weight management.
 
Of Catalent’s more than 50 global sites, Novo Holdings intends to sell three Catalent fill-finish sites and related assets acquired in the merger to Novo Nordisk, in which Novo Holdings has a controlling interest, shortly after the closing of the merger.
 
Catalent is a global provider of drug development, manufacturing, and delivery technologies for pharmaceuticals, biologics, and consumer health products, and has approximatley 14,000 employees.

Read More: Catalent 2Q Fiscal 2024 Results

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters